Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in chronic spontaneous urticaria with blood pressure monitoring
NCT05795153Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of remibrutinib in chronic spontaneous urticaria (CSU), sponsored by Novartis. Primary endpoint: Estimated Mean Change From Baseline at Week 4 in 24-hour Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. Started Apr 2023; status: completed.
02
Drugs
remibrutinib
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT05795153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05795153.